Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARRY-ON: Atezolizumab + Rechallenge Chemotherapy in Relapsed ES-SCLC
NCT06663098Phase 2Recruiting
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Started Jan 2025; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06663098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663098.